Related Experiment Videos
Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling
Liang Lu1, Cuixian Li, Dong Li
1Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou, China.
Abstract:
Malignant gliomas (MGs) are among the most aggressive types of cancers in the human brain. Frequent tumor recurrence caused by a lack of effective therapeutic approaches results in a poor prognosis. Signal transducer and activator of transcription 3 (STAT3), an oncogenic protein, is constitutively activated in MGs and predicts a poor clinical outcome. STAT3 therefore is considered to be a promising target for the treatment of MGs. Cryptotanshinone (CTS), the main bioactive compound from the root of Salvia miltiorrhiza Bunge, has been reported to have various pharmacological effects. However, little is known about its function in MG cells. In this study, we evaluated the effect of CTS on the proliferation of human glioma cell lines (T98G and U87). Our results revealed that CTS significantly suppresses glioma cell proliferation. The phosphorylation of STAT3 Tyr705, but not Ser727, was inhibited by CTS, and STAT3 nuclear translocation was attenuated. Overexpression of constitutively active mutant STAT3C reversed the inhibitory effect of CTS, while knockdown STAT3 showed a similar inhibitory effect as CTS treatment. Following the downregulation of STAT3-regulated proteins cyclinD1 and survivin, cell cycle progression significantly arrested in G1/G0 phase. These results indicate that CTS may be a potential antiproliferation agent for the treatment of MGs and that its mechanism may be related to the inhibition of STAT3 signaling.
Insights
Cryptotanshinone (CTS) inhibits malignant glioma cell proliferation by targeting the STAT3 signaling pathway. This compound suppresses STAT3 phosphorylation and nuclear translocation, leading to cell cycle arrest and offering potential as a novel therapeutic agent.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Malignant gliomas (MGs) are aggressive brain cancers with poor prognoses due to frequent recurrence.
- Constitutive activation of Signal Transducer and Activator of Transcription 3 (STAT3) is common in MGs and linked to poor outcomes.
- STAT3 is a promising therapeutic target for malignant gliomas.
Purpose of the Study:
- To investigate the effect of Cryptotanshinone (CTS) on human glioma cell proliferation.
- To elucidate the mechanism by which CTS affects glioma cells, particularly concerning STAT3 signaling.
Main Methods:
- Treatment of human glioma cell lines (T98G and U87) with CTS.
- Analysis of STAT3 phosphorylation (Tyr705 and Ser727) and nuclear translocation.
- Assessment of cell cycle progression and expression of STAT3-regulated proteins (cyclin D1, survivin).
- Studies involving STAT3C overexpression and STAT3 knockdown.
Main Results:
- CTS significantly suppressed the proliferation of T98G and U87 glioma cells.
- CTS inhibited STAT3 phosphorylation at Tyr705 and attenuated its nuclear translocation.
- Overexpression of STAT3C reversed CTS's inhibitory effects, while STAT3 knockdown mimicked them.
- Downregulation of cyclin D1 and survivin led to G1/G0 phase cell cycle arrest.
Conclusions:
- Cryptotanshinone (CTS) exhibits antiproliferative effects on malignant glioma cells.
- The mechanism involves the inhibition of the STAT3 signaling pathway.
- CTS demonstrates potential as a therapeutic agent for malignant gliomas.
